Caspofungin in combination with amphotericin B against Candida parapsilosis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 941-945

  Barchiesi, Francesco ^a   Spreghini, Elisabetta ^a   Tomassetti, Serena ^a   Giannini, Daniele ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; ECHINOCANDIN; POLYENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; CANDIDA PARAPSILOSIS; CANDIDIASIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSION; DILUTION; DRUG ANTAGONISM; FUNGUS ISOLATION; HOSPITAL INFECTION; IC 50; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; KIDNEY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 33847610663     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00880-06     Document Type: Article

References (23)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.
2. Barchiesi, F., E. Spreghini, A. W. Fothergill, D. Arzeni, G. Greganti, D. Giannini, M. G. Rinaldi, and G. Scalise. 2005. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49:2546-2549.
3. Barchiesi, F., E. Spreghini, M. Maracci, A. W. Fothergill, I. Baldassarri, M. G. Rinaldi, and G. Scalise. 2004. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob. Agents Chemother. 48:3317-3322.
4. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
5. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
6. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
7. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
8. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
9. Graybill, J. R., R. Bocanegra, M. Luther, A. Fothergill, and M. J. Rinaldi. 1997. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. 41:1937-1939.
10. Hossain, M. A., G. H. Reyes, L. A. Long, P. K. Mukherjee, and M. A. Ghannoum. 2003. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. 51:1427-1429.
11. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
12. Messer, S. A., R. N. Jones, and T. R. Fritsche. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol. 44:1782-1787.
13. Mora-Duarte, J., R. Betts, M. C. Rotstein, A. L. Colombo, J. Thompson-Moya, J. Smietana, and R. Lupinacci. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
14. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with easpofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
16. Olson, J. A., J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt. 2005. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother. 49:4895-4902.
17. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, W. E. Dismukes, and NIAID Mycoses Study Group. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
18. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, R. J. Hollis, and the SENTRY Participants Group. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.
19. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
20. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
21. Sugar, A. M., L. Z. Goldani, and M. Picard. 1991. Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence for enhanced activity with combination therapy. Antimicrob. Agents Chemother. 35:2128-2130.
22. Villanueva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535.
23. Zaoutis, T. E., H. M. Greves, E. Lautenbach, W. B. Bilker, and S. E. Coffin. 2004. Risk factors for disseminated candidiasis in children with candidemia. Pediatr. Infect. Dis. J. 23:635-641.